We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

If I’d invested £1,000 in AstraZeneca shares five years ago, here’s what I’d have now

AstraZeneca shares have been the FTSE 100’s standout star over the past five years. But how much would I have made buying this stock five years ago?

| More on:
Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

At present, the total value of the UK’s FTSE 100 index is almost £2.03trn. Yet just 10 mega-cap firms account for £1trn (49.1%) of this total. The biggest Footsie company today is pharmaceutical giant AstraZeneca (LSE: AZN), whose shares have soared in recent years.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

The rise and rise of AstraZeneca shares

On Friday, the AstraZeneca share price closed at 11,746p, down 50p. This values the UK’s biggest healthcare company at £180.8bn. Therefore, this business alone accounts for 8.9% of the entire FTSE 100.

Why is AstraZeneca worth so much? Because its shares have been surging for years. Here’s how the share price has performed over eight periods:

One week-2.2%
One month+5.2%
Three months+10.4%
Six months+16.0%
One year+11.2%
Two years+56.5%
Three years+43.5%
Five years+135.3%

Remarkably, the stock has produced positive returns over all periods ranging from one month to five years. The only fall was a modest decline last week.

Thanks to this outstanding performance, the shares have thrashed the FTSE 100 (+4%) over the past half-decade. In fact, this stock is the Footsie’s #1 performer over the last five years.

However, the above returns exclude cash dividends, which would add a few percentage points a year to these figures.

Investing £1,000 five years ago

To answer the question in my title: how much would I have today had I bought £1,000 of AstraZeneca stock exactly five years ago?

The shares’ 135.3% capital gain over 60 months would have turned my original £1,000 into £2,353 today. That works out at a compound annual growth rate of 18.7% a year. Nice.

However, AstraZeneca shares pay out regular dividends in US dollars. Here are the last five years’ payouts:

Financial year-endTotal dividendsIn £s today
31/12/2022$2.90£2.31
31/12/2021$2.87£2.29
31/12/2020$2.80£2.23
31/12/2019$2.80£2.23
31/12/2018$2.80£2.23
Total$14.17£11.30

My table shows total dividends per share paid out over the past five years add up to £11.30.

The original £1,000 investment would have bought 20 AstraZeneca shares at just under £50 each in 2018. Thus, my total dividends would come to £11.30 times 20, which is £225.90.

Hence, my total return (capital gain plus cash dividends) from AstraZeneca stock over five years would be £2,353 plus £225.90, which equals £2,578.90.

That’s a total return of 157.9%, which works out at a compound annual growth rate of almost 20.9% a year. How I’d love to have earned similar returns from every stock in my portfolio.

What about the future?

Investors who jumped aboard the AstraZeneca bandwagon have seen the company’s revenues more than double over the past five years, leaping from $22.1bn in 2018 to $44.4bn in 2022.

Of course, there’s no guarantee that the rapid growth in both revenues and the share price will continue for another five years. But analysts highly rate CEO Pascal Soriot (appointed back in October 2012) and his leadership team.

That said, I wouldn’t buy the stock today. This is only because my wife and I already have large sums invested in FTSE 100 index trackers. And remember that AstraZeneca accounts for almost 9% of the entire Footsie. Hence, my family already has a decent stake in this great British business!

Cliff D'Arcy has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services, such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool, we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female couple boarding their plane at the airport to go on holiday.
Investing Articles

Can the Rolls-Royce share price reach £15.97 by the end of August?

The Rolls-Royce share price has had a solid run in the last year. Muhammad Cheema takes a look at whether…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 1,200% in 5 years, here’s why Nvidia could still be a brilliant value stock

An exciting new announcement that could reshape the PC industry has just pushed Nvidia stock... well, just about nowhere really.

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

How investing £4.50 a day could set you on the way to a £1,505 monthly second income

How can UK stocks with high dividend yields help investors earn a meaningful second income from the price of a…

Read more »

Investing Articles

Up 103% with a P/E of 261 — is this FTSE 100 stock still worth buying?

One FTSE 100 stock is quietly moving higher while most investors are still looking elsewhere — is the market missing…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

The smart money thinks AI stocks look risky — but is there still a chance to buy?

According to fund managers, the AI trade is getting crowded. But they still seem to think it’s the place to…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Barclays shares are 11% below their 52-week high. Could they be a bit of a bargain to consider?

Overpriced or one of the FTSE 100’s hidden gems? James Beard takes a closer look at how the market is…

Read more »

Stack of one pound coins falling over
Investing Articles

Down 65% but yielding 6.7% – is this beaten-down UK stock now a generational bargain?

Harvey Jones says this UK stock is one of the worst FTSE 100 performers but there are sound reasons to…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this FTSE stock really 46% undervalued?

Analysts reckon this FTSE stock should be worth nearly 50% more. James Beard considers why there’s so much positivity surrounding…

Read more »